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Abstract | Mitral regurgitation (MR) is a common, progressive, and difficult-to-manage disease. MR is 
dynamic in nature, with physiological fluctuations occurring in response to various stimuli such as exercise 
and ischaemia, which can precipitate the development of symptoms and subsequent cardiac events. In 
both chronic primary and secondary MR, the dynamic behaviour of MR can be reliably examined during 
stress echocardiography. Dynamic fluctuation of MR can also have prognostic value; patients with a marked 
increase in regurgitant volume or who exhibit increased systolic pulmonary artery pressure during exercise 
have lower symptom-free survival than those who do not experience significant changes in MR and systolic 
pulmonary artery pressure during exercise. Identifying patients who have dynamic MR, and understanding 
the mechanisms underlying the condition, can potentially influence revascularization strategies (such as the 
surgical restoration of coronary blood flow) and interventional treatment (including cardiac resynchronization 
therapy and new approaches targeted to the mitral valve).
Lancellotti, P. et al. Nat. Rev. Cardiol. 12, 212–219 (2015); published online 10 February 2015; doi:10.1038/nrcardio.2015.16
Introduction
Mitral regurgitation (MR) is a common and progressive 
condition that is difficult to manage clinically.1,2 MR 
results from several heterogeneous conditions, includ­
ing disorders of the mitral valve leaflets, mitral annulus, 
chordae tendineae, papillary muscles, and the left ven­
tricle.3 Strategies for the treatment of MR are typically 
based on a patient’s symptomatic status, and the aetiol­
ogy and the consequences of MR, as assessed during 
echocardiography at rest.1,2 MR is dynamic, with physio­
logical fluctuations occurring in response to haemo­
dynamic changes in the cardiocirculatory system, which 
can precipitate the development of symptoms and subse­
quent cardiac events.4–6 The dynamic nature of MR has 
been investigated in patients with various acute cardiac 
conditions, particularly those with chronic degenera­
tive or secondary MR.7,8 Stress echocardiography has an 
important role in the evaluation of fluctuating MR by 
providing new prognostic insights and risk stratifica­
tion parameters, which can help to define the optimal 
timing of intervention.9–12 In this Review, we discuss the 
characteristics of dynamic MR and the potential mecha­
nisms underlying its development, as well as the optimal 
s trategies to treat the condition. 
Factors that influence MR
Ischaemia-induced acute MR
Acute MR is a potentially life­threatening complication 
of acute myocardial ischaemia and infarction.13 Acute 
MR commonly occurs as a secondary complication of 
acute left ventricular (LV) remodelling and dysfunction 
without structural valvular abnormalities, resulting from 
increased leaflet tethering and reduced mitral closing 
forces.14 However, the severity of secondary MR varies 
widely, and even a mild form of MR in the acute setting 
of myocardial infarction is associated with poor progno­
sis.15 Patients might also present with acute dyspnoea or 
flash pulmonary oedema.16 Medical therapy for patients 
with acute ischaemic MR with or without myocardial 
necrosis is dependent on the underlying pathophysio­
logy. In patients with myocardial ischaemia or infarction, 
restoration of blood flow to the affected territory, often 
the right or circumflex coronary artery, might be suffi­
cient to reduce regurgitation. Early thrombolysis, when 
limited to the inferior wall, might also reduce localized 
LV remodelling and MR.17 Furthermore, early revascu­
larization also reduces mortality in patients with acute 
ischaemic MR presenting with shock.18
Chronic dynamic secondary MR
Chronic secondary MR is present in more than half of 
patients with symptomatic systolic heart failure due to 
ischaemic or nonischaemic cardiomyopathy.19 Secondary 
MR results from the geometrical distortion of the subval­
vular apparatus, which occurs secondary to LV enlarge­
ment and impaired contractility.3,4,20,21 Secondary MR is 
a disease of the ventricles rather than of the valves per se, 
and is classified as type IIIb in Carpentier’s surgical clas­
sification of mitral valve pathology.11,22 The incidence 
and clinical importance of secondary MR is largely 
underestimated, in part owing to the insensitive nature of 
the physical examination. The presence of secondary MR 
in patients with LV dysfunction conveys an adverse prog­
nosis, with a graded relationship between the severity 
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of regurgitation and reduced survival.23 Based on previ­
ous outcome studies, secondary MR is defined as severe 
when the effective regurgitant orifice area (EROA) is 
≥20 mm.2,24 Chronic secondary MR is dynamic, and its 
severity can vary over time, depending on the dynamic 
interplay between tethering and closing forces, and on 
Key points
 ■ Mitral regurgitation (MR) often varies dynamically with changes in 
loading conditions
 ■ Dynamic fluctuation of MR can precipitate symptoms and induce left 
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valve approaches
the physiological and pharmacological factors that can 
alter this balance.14 Symptoms can, therefore, often seem 
to be out of proportion to the degree of MR at rest.25
Exercise-induced changes in MR
The dynamic behaviour of secondary MR can be reliably 
examined during exercise echocardiography.5–8 More than 
30% of patients with secondary MR have a clinically sig­
nificant dynamic increase in MR during exercise; EROA 
at rest, therefore, does not predict EROA during exercise 
(Figure 1).26,27 Patients who have an exercise­induced 
increase in the severity of secondary MR experience 
reduced stroke volume adaptation during testing, and 
often develop pulmonary hypertension and dynamic LV 
dyssynchrony; all these changes contribute to the limita­
tion in exercise capacity.28 In patients with previous infe­
rior myocardial infarcts, a lack of contractile reserve can 
lead to increased annular size and leaflet tethering of the 
mitral valve during exercise, thereby expanding mitral 
valve tenting area and increasing the EROA.5 Similarly, 
in patients with anterior myocardial infarcts, apical 
displacement of the mitral leaflet can lead to increased 
leaflet tenting. In both infarct territories, systolic bulging 
of the mitral leaflets is the major determinant of dynamic 
MR. An exercise­induced increase in the severity of MR, 
as indicated by an EROA ≥13 mm2, confers a high risk 
of morbidity (such as acute pulmonary oedema and 
w orsening heart failure) and mortality.7,11
Effect of anaesthetics and dobutamine on MR
Secondary MR also varies dynamically with loading con­
ditions that modulate LV volume.14 Regurgitant volume 
decreases substantially in response to unloading drugs, 
which is achieved through a reduction in EROA, but 
not through a change in the gradient across the mitral 
valve. Reduction of orifice area is likely to be related to a 
decrease in LV volume.29 Such a dramatic variation in MR 
is observed most commonly in the operating room, where 
anaesthetic induction can reduce moderate MR to trace 
levels, confounding decisions regarding the need for mitral 
valve repair.30 Inotropic agents can also reduce the severity 
of MR (Figure 2).31 The underestimation of intraoperative 
MR might contribute to an i naccurate diagnosis of recur­
rent MR after isolated CABG surgery.32 Dobutamine infu­
sion causes a marked rise in mean forward stroke volume 
with a decrease in regurgitant volume. Such a reduction 
is partially related to an increase in contractility, as sug­
gested by the rise in the ratio of peak systolic pressure over 
end­systolic volume. Dobutamine reduces the severity of 
MR, mainly as a result of a reduction in EROA. However, 
dobutamine infusion can also induce severe and extensive 
ischaemia, which results in worsening of MR.14
Effect of loading challenges on MR
In the operating theatre, a preload and afterload chal­
lenge test is sometimes used to minimize the effects of 
anaesthetic induction on secondary MR.33 A rapid fluid 
filling test is performed until mean capillary wedge pres­
sure reaches 15–18 mmHg. If the intensity of MR does not 
increase, phenylephrine is administered until the mean 
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Figure 1 | Transthoracic Doppler echocardiogram of a patient with symptomatic 
ischaemic cardiomyopathy, severe left ventricular dysfunction, and moderate 
secondary mitral regurgitation at rest. a | Patient at rest. b | During exercise, a 
clinically significant increase in mitral regurgitation combined with dyspnoea and 
pulmonary hypertension was observed. c | After CABG surgery and mitral valve 
repair, the patient improved clinically and no substantial increase in mitral 
regurgitation was observed during exercise.
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arterial blood pressure rises to 100 mmHg. However, 
careful attention should be paid to avoid errors in MR esti­
mation during phenylephrine infusion. The ultimate effect 
of the phenylephrine on MR severity can be challenged by 
the interplay between the recruitment of LV coaptation 
forces and the increase in systemic arterial pressure, which 
can reduce and increase MR, respectively. Alternatively, 
manoeuvring the patient into the Trendelenburg position 
using a specialized bed with a 40° inclination can induce 
fast LV volume loading without substantial arterial pres­
sure changes, and can be used to elicit tethering LV forces 
and a related increase in MR. The manoeuver can be 
carried out in conscious patients to induce MR, and sub­
sequently in the operating theatre to reproduce the site of 
valve regurgitation, especially to guide beating­heart per­
cutaneous therapy (also known as the edge­to­edge Alfieri 
technique) in patients with fluctuating MR (Figure 3). 
Fluctuating degenerative primary MR
In asymptomatic patients with moderate­to­severe 
primary MR (such as that caused by mitral prolapse or 
rheumatic disease), exercise stress echocardiography can 
induce a marked increase in MR severity (indicative of 
dynamic MR), which occurs in approximately one­third 
of all patients.8,12 Of note, MR severity increases by 
one grade (from moderate to severe, by measuring the 
proximal isovelocity surface area) in 30% of all patients 
during exercise.8,34 This phenomenon is often associ­
ated with exercise­induced pulmonary hypertension.10 
Patients with a marked increase in regurgitant volume 
or who develop pulmonary hypertension (defined as sys­
tolic pulmonary artery pressure >60 mmHg) during exer­
cise have lower symptom­free survival than those who 
do not experience significant changes in MR and systolic 
pulmonary artery pressure during exercise. When com­
bined with pulmonary hypertension, exercise­induced 
right ventricular dysfunction is an independent predictor 
of surgery­free survival in primary MR.35 The absence of 
contractile reserve during exercise, defined as no or 
limited increase in LV ejection fraction and global longi­
tudinal function, predicts postoperative LV dysfunction 
and impaired outcome, even in patients with apparently 
preserved LV ejection fraction (>60%).12
Management of dynamic MR
Medical therapy for the treatment of dynamic MR is 
limited in its efficacy. A combination of angiotensin­
converting­enzyme inhibitors and β­blockers can limit 
the adverse LV remodelling process, but a decrease 
in the incidence or severity of dynamic MR has not been 
demonstrated by this approach.32 In patients with heart 
failure and secondary MR, medical treatment should 
follow current ESC and AHA/ACC guidelines,1,2 which 
recommend the use of β­blockers and angiotensin­
converting­enzyme inhibitors or angiotensin­receptor 
blockers. The use of vasodilators such as nitrates before 
exercise can mitigate the worsening of dynamic MR.31
The advantages of surgical mitral valve repair over 
surgical mitral valve replacement are well­documented 
and the trend towards increased surgical repair proce­
dures will continue.36 The treatment for primary MR 
is straightforward, with a primary aim of timely inter­
vention to prevent adverse LV remodelling and dys­
function.1,2 The management of secondary MR is more 
challenging, because the mitral valve is not the primary 
cause of the disease. Furthermore, correcting MR without 
changing LV geometry is not guaranteed to be bene­
ficial.14 The ability to identify patients who have dynamic 
aggravation of MR, together with knowledge of the 
underlying mechanism, can influence revascularization 
strategies and concomitant mitral valve interventional 
procedures (Box 1).
Indications for treatment
Secondary MR
The management of patients with chronic secondary 
MR remains challenging (Figure 4). Current guidelines 
advocate mitral valve surgery in severe secondary MR 
at the time of CABG surgery.1,2 The ESC guidelines con­
sider combined surgery (CABG surgery plus mitral valve 
surgery) as a class IIa, level of evidence B indication, when 
LV ejection fraction is <30%, there is evidence of viability, 
and an option exists for revascularization. Surgery can also 
be considered in patients with severe MR, who remain 
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Figure 2 | Transthoracic Doppler echocardiogram showing a substantial 
decrease in secondary mitral regurgitation severity observed after dobutamine 
administration. a | Effective regurgitant orifice area = 33 mm2. b | Effective 
regurgitant orifice area = 18 mm2.
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Figure 3 | Transoesophageal Doppler echocardiogram in a patient with a clinical 
history of flash pulmonary oedmea and fluctuating mitral regurgitation. a | Baseline 
measurement and b | during the Trendelenburg manoeuver.
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symptomatic despite optimal medical management or 
cardiac resynchronization therapy (CRT) and have few 
comorbidities, when revascularization is not indicated.1,2
Mitral valve repair is not unanimously recommended 
as a therapeutic option for chronic moderate second­
ary MR at the time of CABG surgery. The AHA/ACC 
guidelines give combined surgery in patients undergo­
ing CABG surgery a class IIb, level of evidence C indica­
tion, whereas the ESC guidelines give combined surgery 
a class IIa, level of evidence C indication in patients with 
shortness of breath and exercise pulmonary hypertension 
in the setting of dynamic worsening of secondary MR.1,2 
Previous studies have provided some insight into the 
benefit of performing mitral annuloplasty together with 
CABG surgery in patients with exercise­induced eleva­
tions in MR.37,38 Patients with either no clinically relevant 
changes or exercise­induced reductions in secondary 
ischaemic MR as a result of recruitable function in the 
inferobasal wall, which is an improvement in regional 
myocardial motion, might be referred for CABG surgery 
only.32 However, larger outcome studies to examine the 
benefit of combined surgery in relation to results from 
exercise echocardiography are needed. Moreover, the 
additional risk of mitral valve surgery is not negligible, 
particularly in patients with comorbidities and poor LV 
function. Very ill patients or elderly individuals with a 
history of atrial fibrillation might be treated conserva­
tively with revascularization alone or with a percutaneous 
approach,39 although the treatment strategy also depends 
on the individual’s risk profile.
Degenerative MR
Degenerative MR involves mitral valve prolapse (type II) 
and covers a large spectrum of lesions, from an isolated 
scallop prolapse to multisegment prolapse. The loca­
tion of the prolapse, the presence of valvular or annular 
calcifications, and the severity of annulus dilatation can 
affect the feasibility and choice of surgical or percutane­
ous repair techniques.3 Chronic severe primary MR can 
lead to LV volume overload. Surgery is the recommended 
therapeutic option for patients who are symptomatic at 
rest or during exercise testing.1,2 The major determi­
nants of surgical outcome and mortality in asympto­
matic patients include preoperative resting LV ejection 
fraction <60%, end­systolic diameter >40 mm, recurrent 
atrial fibrillation, and pulmonary artery systolic pres­
sure >50 mmHg.1,2 These factors are common indica­
tions for mitral valve surgical repair. Surgery can also be 
considered in asymptomatic patients with preserved LV 
function, high likelihood of durable repair, low surgical 
risk, and systolic pulmonary artery pressure ≥60 mmHg 
during exercise.1,2 Currently, neither the ESC nor the 
AHA/ACC guidelines recommend intervention based on 
exercise­induced changes in the severity of degenerative 
MR. However, in patients with substantial LV remodel­
ling and moderate MR at rest who develop severe MR 
during exercise, mitral valve repair might be consid­
ered. Similarly, patients with limited contractile reserve 
during exercise (possibly an indication of subclinical LV 
d ysfunction) might benefit from early elective surgery.
Treatment strategies for MR
Surgical options
Therapeutic options for the treatment of primary or sec­
ondary MR include coronary artery revascularization 
alone, mitral valve replacement, and mitral valve repair 
with or without CABG surgery. Repair techniques for 
primary MR are well described; the success of the inter­
vention depends upon the surgeon’s skill and the severity 
of valve lesions.36 At present, the efficacy of surgery in 
patients with exercise test results that favour mitral valve 
repair for the treatment of degenerative MR is unknown.
In secondary MR, CABG surgery alone does not 
result in a clinically significant change in MR grade, 
and a substantial percentage of patients with mild­to­
moderate MR have an increase in severity or recurrence 
of MR during follow­up.30,40 Although CABG surgery 
alone seems to produce long­term survival rates similar 
to those for combined surgery, patients with untreated 
secondary MR at the time of isolated CABG surgery 
have an increased risk of hospitalization for heart failure 
during follow­up.41,42 The main aim of combined surgery 
is to improve long­term functional status and quality of 
life.1,2 In the RIME trial,38 mitral annuloplasty at the time 
of CABG surgery in patients with moderate ischaemic 
MR, present either at rest or developed upon physical 
exertion, was associated with improved functional capac­
ity, reversal of adverse LV remodelling, reduced severity 
of MR, and decreased B­type natriuretic peptide levels. 
In a further randomized study, combined stringent 
restrictive annuloplasty with CABG surgery in patients 
Box 1 | Evaluation of patients with MR to guide treatment
Clinical and echocardiographic evaluation31
Signs and symptoms of heart failure, dyspnoea, 
flash pulmonary oedema, angina, and systemic 
venous congestion
Optimal medical therapy
Identification of modifiable factors
 ■ Atrial fibrillation
 ■ Arterial hypertension
 ■ Anaemia
 ■ Water and sodium intake (diet, drug-mediated)
 ■ Ischaemic myocardial dysfunction
 ■ Viable myocardium
 ■ Left ventricular asynchrony
 ■ Papillary muscle asynchrony
Evaluation of mitral valve configuration4
Substantial regurgitation at rest or during changes 
in loading conditions (for example, exercise and 
loading manipulation)
Anatomofunctional mechanisms
 ■ Severity of mitral valve deformation (symmetrical 
malapposition [tenting area], systolic coaptation depth, 
posterior–lateral angle, presence and longitudinal 
extension of coaptation [manipulation at baseline and 
after loading])
 ■ Central origin and intercommissural width of 
regurgitant jet
 ■ Presence and extent of mitral valve calcification
 ■ Presence and extent of mitral valve prolapse
Mitral valve area
Abbreviation: MR, mitral regurgitation.
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with mild­to­moderate secondary MR improved func­
tional status and inhibited the dynamic changes in MR 
observed during exercise at follow­up.36 Conversely, 
CABG surgery alone did not prevent an increase in MR 
induced by physical exertion, which contributed to per­
sistent exercise intolerance. Remodelling annulo plasty 
using a prosthetic undersized ring is the technique of 
choice for patients with Carpentier’s type IIIb dysfunc­
tion MR, or MR that involves restricted mitral leaflet 
motion during the end­systolic phase. This technique 
provides good results in selected patients with minimal 
LV dilatation and little mitral valve tenting.41,43,44 
Although initially effective in most patients, persistent or 
recurrent MR, which occurs mid­term to long­term after 
the procedure (>3 months), is often observed in patients 
with severe mitral valve deformation and LV enlarge­
ment, contributing to the ongoing adverse LV remodel­
ling process and worsened cardiovascular outcome.45 
In the presence of severe mitral leaflet tethering and 
LV dilatation, subvalvular approaches such as chordal 
cutting, papillary muscle repositioning, and edge­to­edge 
leaflet approximation have been proposed to enhance 
the effectiveness of mitral valve annuloplasty.46,47 Mitral 
valve replacement using bioprosthetic heart valves that 
preserve the entire subvalvular apparatus might be a 
valid alternative to mitral valve repair in patients with 
comorbid diseases, complex regurgitant jets, and severe 
remodelling of the mitral valve apparatus.48 This tech­
nique can be recommended in patients with severe mitral 
valve tethering (coaptation distance >1 cm) in secondary 
MR, where it is likely to produce similar survival rates 
and less recurrent MR than mitral valve repair.49
Cardiac resynchronization therapy
The development of CRT has substantially changed 
the treatment of patients with advanced heart failure. 
Currently, CRT is an adjunctive treatment indicated for 
the treatment of patients with LV systolic dysfunction 
and prolonged QRS duration, who remain symptomatic 
despite optimal drug therapy.1,2 CRT improves exercise 
tolerance, in addition to providing symptomatic bene fits 
and reducing mortality.50 The potential mechanisms for 
the benefits associated with CRT are mainly related to 
optimized LV filling, synchronized LV electro mechanical 
coupling resulting in an improvement in LV myocardial 
performance, and a reduction of MR both at rest and 
during exercise.51 The beneficial effect of CRT on sec­
ondary MR occurs through the reversal of adverse LV 
remodelling, improved LV systolic function, increased 
closing force (indicated by a change in EROA, which 
was directly related to the increase in LV dP/dt) and 
improved coordinated timing of mechanical activation 
of the papillary muscles.52,53 However, these bene fits 
are reversible, and studies have demonstrated that CRT 
withdrawal after 6 months of implantation acutely results 
in MR recurrence.54,55 In addition, owing to the smaller 
benefits in LV remodelling derived from CRT in patients 
with ischaemic cardiomyopathy, the regression of MR is 
subsequently less in this subset of patients. The beneficial 
effect of CRT on MR that worsens upon exercise occurs 
late after CRT implantation (>3 months), and parallels 
the timeframe of reversal of LV remodelling and reduc­
tion in LV dynamic dyssynchrony.55 According to two 
studies, the expected rate of attenuation of e xercise­
induced secondary MR is approximately 30%.56,57 How­
ever, CRT reduces the severity of secondary MR, but does 
not prevent the development of dynamic MR in most 
patients. In these individuals, combining CRT with a 
percutaneous mitral valve approach might be of benefit. 
The proposal that exercise worsens dyssynchrony, which 
consequently increases MR, warrants further study and 
might indicate the need for CRT in affected patients.58,59
Percutaneous mitral valve intervention
In the past 5 years, the introduction of percutaneous 
mitral valve intervention (PMVI) techniques has opened 
new frontiers in MR therapy, by eliminating the need 
for thoracotomy and extracorporeal circulation.60 PMVI 
techniques can correct MR by means of direct or indi­
rect reduction of mitral annular dilatation, or through 
treatment of the primary or secondary abnormalities 
of the mitral apparatus. The efficacy and feasibility of 
PMVI is dependent on careful selection of patients with 
a suitable clinical profile, and on an accurate evalua­
tion of the mechanism and severity of their MR using 
integrated Doppler echocardiography.61 Among PMVI 
techniques, the MitraClip® system (Abbott Vascular 
Inc., USA), which can reproduce the edge­to­edge sur­
gical procedure, is the only percutaneous therapeutic 
approach that has been clinically validated.62,63 Studies 
on numerous other PMVI techniques are still in the 
experimental phase.
The selection of patients suitable for PMVI therapy 
requires a different clinical–instrumental approach in 
those with secondary MR compared with those with 
primary degenerative MR. The selection of patients 
with secondary MR eligible for echocardiography is a 
challenging clinical issue, owing to the complex inter­
play between LV disease and associated dynamic valve 
regurgitation. Secondary MR is affected by loading 
Nature Reviews | Cardiology
Yes No
Unexplained dyspnoea
Nonischaemic pulmonary oedema
Exercise-induced MR/PHT
Inducible ischaemia
+ +
CABG surgery + MVS CRT if indicated MitraClip®/other strategies
Revascularization not indicated Revascularization indicated*
Moderate secondary MR
EROA = 10–20 mm2
Figure 4 | Management of patients with moderate secondary M  and left 
ventricular dysfunction. *CABG surgery is an alternative option in patients with 
posterior–lateral wall viability and exercise-induced decrease in secondary MR. 
MitraClip® is manufactured by Abbott Vascular Inc., USA. Abbreviations: CRT, 
cardiac resynchronization therapy; EROA, effective regurgitant orifice area; MR, 
mitral regurgitation; MVS, mitral valve surgery; PHT, pulmonary hypertension.
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forces that might influence the degree of remodelling 
and LV contraction.29 Echo–Doppler mapping and 
inter commissural extension of the regurgitant lesion 
is essential for predicting the site of clip implantation, 
to determine whether an additional clip is needed, 
and to predict the risk of postprocedural residual ste­
nosis. The ideal indication for MitraClip® therapy in 
patients with secondary MR involves a mitral valve 
lesion with symmetrical systolic leaflet tenting and main­
tenance of systolic coaptation shape within a depth of 
10 mm and ≤2 mm of longitudinal extension.60 However, 
these echocardiographic criteria can be dynamically 
changed by LV load and functional conditions, which 
can have a s ubstantial effect on the characteristics of 
target­valve lesion.
As such, the indication, strategic planning, and effi­
cacy of repair of the MitraClip® procedure in patients 
with fluctuating MR remains a clinically relevant con­
sideration. Several issues need to be addressed: the 
identification and possible treatment of underlying 
mechanisms subtending fluctuating MR before consid­
ering MitraClip® therapy; intraprocedural inducibility of 
MR to guide clip positioning and to establish the number 
of clips required; and re­evaluation of the inducibility of 
MR after clip implantation.
Percutaneous MitraClip® therapy can also be applied 
to central prolapsing lesions with poor intercommissural 
extension (width <12 mm) and a limited systolic coapta­
tion gap (<10 mm) in the absence of annular dilatation. 
MitraClip® therapy for degenerative primary MR, in the 
absence of extensive clinical application and randomized 
studies, cannot be considered equivalent to surgical 
repair, and should be performed only in patients with 
adequate valve lesions and at high operative risk.1,2 Mitral 
valve prolapse is a dynamic lesion resulting from exces­
sive valve tissue, and leads to coaptation loss and related 
regurgitation. However, the prolapse threshold can be 
decreased by LV volume­related tethering and increased 
by contraction­based coaptation forces.8 Consequently, 
evaluation of the targeted prolapsing lesion should take 
into account the potential fluctuation caused by LV load 
conditions, which can mask or unmask the prolapse; this 
assessment can have a substantial effect on MitraClip® 
feasibility and efficacy. This complex interplay between 
LV forces and the threshold of the prolapse is lost upon 
rupture of the chordae tendinae, simplifying the MR 
mechanism, which then becomes dependent solely on 
LV systolic pressure.14 Therefore, MitraClip® therapy 
guidance might require different approaches in patients 
with isolated prolapse compared with those with rup­
tured chordae. Nonphysiological LV load (for example, 
as a result of administration of unloading drugs such as 
diuretics) should be carefully considered and optimized 
to avoid the opposite effects on MR. For example, low 
preload or afterload conditions might result in an over­
estimation of prolapse­related MR or an underestima­
tion of flail­related MR, respectively. The Trendelenburg 
manoeuver might attenuate prolapse, while increasing 
flail­related MR; the opposite effect can be observed 
using an anti­Trendelenburg manoeuver.
Percutaneous mitral annuloplasty
Various percutaneous techniques that mimic surgical 
annuloplasty have been tested in both animal models 
and the clinical setting.45,46,60,64–68 Percutaneous devices 
used to reshape the mitral annulus can be separated into 
indirect and direct types; the former are positioned in the 
coronary sinus, whereas the latter addresses the mitral 
annulus. Indirect annulopasty involves the placement of 
a device into the coronary sinus to promote favourable 
annulus remodelling, thereby optimizing leaflet coapta­
tion. In direct annulopasty, a device is implanted into the 
annulus, using the retrograde (into the left ventricle via 
the aorta) or the transatrial (transeptal) approach.
Echocardiographic MR analysis for annuloplasty is 
crucial for patient selection. Similar to the criteria for 
surgical annuloplasty, the ideal lesion includes type I 
(incomplete copatation due to annular dilatation or 
deformation) or type IIIb (functional leaflet tethering) 
with symmetric leaflet malapposition and a coaptation 
depth <1 cm.3 Structural abnormalities of the mitral 
valve (type II and type IIIa), or recognized tethering 
shapes that are typically associated with unsuccessful 
surgical annuloplasty (asymmetric or extreme teth­
ering), should not be treated using the percutaneous 
approach. Fluoroscopy and transoesophageal echo­
cardiography are used to determine the final position 
of the annuloplasty devices.61 Transoesophageal echo­
cardiography is performed to guide annulus reshaping 
and other related changes in MR. Successful reduction 
of MR requires careful attention to LV load condi­
tions to avoid misleading procedural results. Given the 
close proximity of the circumflex artery to the coro­
nary sinus, ischaemia­related MR worsening should be 
excluded before co nsidering the transcoronary sinus 
procedure unsuccessful.69
Other strategies
Although they are currently unavailable for clinical 
use, some percutaneous devices have been considered 
for secondary MR treatment to promote favourable 
LV remodelling with a direct approach.1 Some devices 
are designed to correct the distortion in LV shape and 
annular dilatation using a system of chordae release 
through the left ventricle between the two papillary 
muscles, with subsequent anteroposterior LV reduc­
tion, by shortening of the implanted chordae.70 Another 
device utilizes a beating­heart implantation of a circu­
lar band with inflatable chambers at the base of the left 
ventricle.71 Other percutaneous techniques consist of a 
direct beating­heart chordae implantation using a trans­
apical approach to treat prolapse or ruptured chordae 
tendinae in selected patients with degenerative MR.72 
Transcatheter mitral valve replacement is another inno­
vative approach.63 Echocardiographic assessment of the 
dynamic changes in MR is crucial to guide these proce­
dures and monitor the effects of device implantation on 
mitral valve target lesions. Careful attention is required 
to recognize MR fluctuation to establish the therapeu­
tic benefit of the proposed new techniques, given the 
complex pa thophysiology of mitral valve incompetence.
REVIEWS
© 2015 Macmillan Publishers Limited. All rights reserved
218 | APRIL 2015 | VOLUME 12 www.nature.com/nrcardio
Conclusions
Transient worsening of MR can be the underlying cause 
of clinical destabilization with exertional dyspnoea, acute 
pulmonary oedema, and impaired clinical outcome. 
Loading­change stress echocardiography is an impor­
tant clinical tool in the assessment and management of 
patients with fluctuating MR. Although further evidence 
is needed to determine the benefit of combined surgery 
in relation to loading changes on echocardiography, the 
technique has already entered the clinical arena and has 
contributed to defining the optimal timing of interven­
tion in patients with MR. Current therapies used to treat 
fluctuating MR are customized according to its aetiol­
ogy, and include mitral valve surgery associated with 
coronary revascularization, cardiac resynchronization 
therapy, and new mitral valve approaches.
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